life-sciences-consulting
(5)
The Hardest Part of a Breakthrough Is Explaining It
SIMPSON Healthcare built a business in the narrow gap between discovering a therapy and making its science understood. Inside IQVIA, that small Connecticut agency now has a much larger map.
The Medicine Was Approved. Then the Hard Part Began.
Lucid Group built a business around an awkward truth in medicine: approval is only the beginning. Its job is to move evidence through the far messier machinery of belief, behaviour and clinical practice.
RHMM and the art of arriving before the launch
Shire had a new eye drug and a small ophthalmics team. RHMM helped prepare the professional audience - a revealing assignment for a company built around science, relationships, and getting the work done.
ZoomRx Wants to Stop Pharma From Paying Twice for the Same Answer
For years, a pharma study ended with a deck and a folder. ZoomRx is betting that its 60,000-plus-member panel, 700 million benchmark data points and new AI products can turn those forgotten files into a living commercial memory.
Akira Robinson
Akira Robinson is a biotech and pharmaceutical commercialization leader with roughly two decades of experience turning early-stage science into market-ready medicine. He is a Partner and Chief Experience Officer at the life-sciences consultancy Scimitar Inc. and serves as interim Chief Commercial Officer at Nucleus RadioPharma. He built and scaled the launch practice at EVERSANA to more than 20 consultants, and has stepped into interim CCO and COO seats across the industry. With a Harvard biochemistry degree, a Johns Hopkins biotech master's, and a stint as a Wall Street biotech equity analyst, he blends scientific fluency with commercial operating chops, lately focused on radiopharmaceutical therapies and AI-driven commercialization.